The Role of Immunotherapy in Multiple Myeloma
Multiple myeloma is the second most common hematologic malignancy. The treatment of this disease has changed considerably over the last two decades with the introduction to the clinical practice of novel agents such as proteasome inhibitors and immunomodulatory drugs. Basic research efforts towards...
Main Authors: | Mehmet Kocoglu, Ashraf Badros |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2016-01-01
|
Series: | Pharmaceuticals |
Subjects: | |
Online Access: | http://www.mdpi.com/1424-8247/9/1/3 |
Similar Items
-
Immunotherapy in Multiple Myeloma
by: Cinnie Yentia Soekojo, et al.
Published: (2020-03-01) -
Editorial: Exploiting the Immune System to Treat Multiple Myeloma: From Transplantation to Novel Treatment Approaches
by: Niels W. C. J. van de Donk, et al.
Published: (2020-10-01) -
Immunotherapeutic strategies targeting B cell maturation antigen in multiple myeloma
by: Yi Fang, et al.
Published: (2021-01-01) -
Novel Experimental Drugs for Treatment of Multiple Myeloma
by: Offidani M, et al.
Published: (2021-03-01) -
Development of Novel Immunotherapies for Multiple Myeloma
by: Ensaf M. Al-Hujaily, et al.
Published: (2016-09-01)